A Phase II, Randomized, Double-blind, Controlled Safety and Immunogenicity Trial of Typhoid Conjugate Vaccine in Children Under 2 Years of Age in Ouagadougou, Burkina Faso: A Methods Paper

被引:8
|
作者
Laurens, Matthew B. [1 ]
Sirima, Sodiomon B. [2 ]
Rotrosen, Elizabeth T. [1 ,4 ]
Siribie, Mohamadou [2 ]
Tiono, Alfred [2 ]
Ouedraogo, Alphonse [2 ]
Liang, Yuanyuan [3 ]
Jamka, Leslie P. [1 ]
Kotloff, Karen L. [1 ]
Neuzil, Kathleen M. [1 ]
机构
[1] Univ Maryland, Sch Med, Ctr Vaccine Dev & Global Hlth, 685 W Baltimore St Room 480, Baltimore, MD 21201 USA
[2] Grp Rech Act Sante, Ouagadougou, Burkina Faso
[3] Univ Maryland, Sch Med, Dept Epidemiol & Publ Hlth, Baltimore, MD 21201 USA
[4] Boston Univ, Sch Med, Boston, MA 02215 USA
基金
比尔及梅琳达.盖茨基金会;
关键词
child; typhoid-paratyphoid vaccines; Burkina Faso; immunogenicity; conjugate; ACELLULAR PERTUSSIS-VACCINE; ENTERICA SEROVAR TYPHI; SUB-SAHARAN AFRICA; IMMUNE-RESPONSE; SALMONELLA; MULTICENTER;
D O I
10.1093/cid/ciy1104
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The recent Typhoid Fever Surveillance in Africa Program demonstrated an overall adjusted incidence of typhoid fever 2-3 times higher than previous estimates in Africa. Recently, a single-dose typhoid conjugate vaccine that allows infants as young as 6 months old to be vaccinated was prequalified by the World Health Organization (WHO). This Vi-based conjugate vaccine demonstrated robust immunogenicity after 1 dose in infants and children 6 through 23 months of age in India with no safety signal, and is currently being tested for the first time on the African continent in Malawi. The WHO Strategic Advisory Group of Experts recommends studies to evaluate co-administering Vi-typhoid conjugate vaccine (Vi-TCV) with routine childhood vaccines in typhoid-endemic countries. The Burkina Faso immunization schedule includes yellow fever vaccine (YFV) at 9 months and meningococcal A conjugate vaccine (MCV-A) at 15 months, in addition to measles-rubella vaccine at both 9 and 15 months. Co-administration testing of Vi-TCV with these routine vaccinations will provide the data needed to support large-scale uptake of Vi-TCV in sub-Saharan Africa. A randomized, controlled, Phase II trial of Vi-TCV co-administration with the vaccinations routinely given at 9 and 15 months of age is planned in Burkina Faso. The overall aim is to assess the safety and immunogenicity of Vi-TCV when co-administered with YFV at 9 months of age and with MCV-A at 15 months of age. A total of 250 participants (100 infants aged 9-11 months and 150 children aged 15-23 months) will be enrolled. Clinical Trials Registration. NCT03614533. The World Health Organization recently prequalified a single-dose, typhoid conjugate vaccine for children as young as 6 months of age. A randomized, controlled clinical trial will assess the safety and immunogenicity of co-administration with routine childhood vaccines in Burkina Faso.
引用
收藏
页码:S59 / S66
页数:8
相关论文
共 50 条
  • [41] Randomized, Double-Blind Controlled Phase 3 Trial Comparing the Immunogenicity of High-Dose and Standard-Dose Influenza Vaccine in Adults 65 Years of Age and Older
    Falsey, Ann R.
    Treanor, John J.
    Tornieporth, Nadia
    Capellan, Jose
    Gorse, Geoffrey J.
    JOURNAL OF INFECTIOUS DISEASES, 2009, 200 (02): : 172 - 180
  • [42] Safety, immunogenicity, and lot-to-lot consistency of live attenuated varicella vaccine in 1-3 years old children: a double-blind, randomized phase III trial
    Huang, Lili
    Chen, Zhen
    Hu, Yuansheng
    Xie, Zhiqiang
    Qiu, Ping
    Zhu, Lang
    Bao, Manli
    Quan, Yaru
    Zeng, Ji
    Wang, Yanxia
    Cui, Xiaoyu
    Yuan, Liyong
    Xia, Shengli
    Meng, Fanhong
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (04) : 822 - 827
  • [43] Safety and immunogenicity of a single dose, live-attenuated 'tetravalent dengue vaccine' in healthy Indian adults; a randomized, double-blind, placebo controlled phase I/II trial
    Mohanty, Lalitendu
    Prabhu, Madhav
    Mishra, Amit Kumar
    Purty, Anil J.
    Kanungo, Reba
    Ghosh, Goutam
    Kumar, R. Prahan
    Raj, A. Newton
    Bhushan, Sumit
    Jangir, Manoj Kumar
    Gupta, Anu
    Bhakri, Anju
    VACCINE: X, 2022, 10
  • [44] Phase II, Safety and Immunogenicity of RAZI Cov Pars (RCP) SARS Cov-2 Vaccine in Adults Aged 18-70 Years; A Randomized, Double-Blind Clinical Trial
    Mohazzab, Arash
    Mehrabadi, Mohammad Hossein Fallah
    Es-haghi, Ali
    Kalantari, Saeed
    Mokhberalsafa, Ladan
    Setarehdan, Seyed Amin
    Sadeghi, Fariba
    Mokarram, Ali Rezaei
    Moradi, Monireh Haji
    Razaz, Seyad Hossein
    Taghdiri, Maryam
    Ansarifar, Akram
    Lot, Mohsen
    Khorasani, Akbar
    Nofeli, Mojtaba
    Masoumi, Safdar
    Boluki, Zahra
    Erfanpoor, Saeed
    Amiri, Fahimeh Bagheri
    Filsoof, Sara
    Mohseni, Vahideh
    Esmailzadehha, Neda
    Safari, Shiva
    Shahsavan, Masoumeh
    Bayazidi, Shnoo
    Derakhshani, Maryam Raghami
    Rabiee, Mohammad Hasan
    Golmoradi-Zadeh, Rezvan
    Khodadoost, Behnam
    Solaymani-Dodaran, Masoud
    Banihashemi, Seyed Reza
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2023, 112 (12) : 3012 - 3021
  • [45] Phase II randomized, double blind, placebo controlled, clinical trial of safety and immunogenicity of an inactivated SARS-CoV-2 vaccine FAKHRAVAC in adults aged 18-70 years
    Gholami, Fatemeh
    Farahani, Ramin Hamidi
    Rahjerdi, Ahmad Karimi
    Ahi, Mohammadreza
    Sheidaei, Ali
    Gohari, Kimiya
    Rahimi, Zahra
    Ansarifar, Akram
    Basiri, Pouria
    Moradi, Milad
    Jahangiri, Arash
    Naderi, Kosar
    Ghasemi, Soheil
    Khatami, Pezhman
    Honari, Mohsen
    Khodaverdloo, Samane
    Shooshtari, Mohammad
    Azin, Hajar Mehr
    Moradi, Sohrab
    Shafaghi, Batool
    Allahyari, Hossein
    Monazah, Arina
    Poor, Ali Khodaei
    Taghva, Zahra
    Bakhshande, Hooman
    Nia, Mohammad Karimi
    Dodaran, Masoud Solaymani
    Forooghizade, Mohsen
    BMC INFECTIOUS DISEASES, 2023, 23 (01)
  • [46] Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Investigate the Immunogenicity and Safety of a West Nile Virus Vaccine in Healthy Adults
    Biedenbender, Rex
    Bevilacqua, Joan
    Gregg, Anne M.
    Watson, Mike
    Dayan, Gustavo
    JOURNAL OF INFECTIOUS DISEASES, 2011, 203 (01): : 75 - 84
  • [47] Immunogenicity and Safety of Inactivated Enterovirus 71 Vaccine in Children Aged 36-71 Months: A Double-Blind, Randomized, Controlled, Non-inferiority Phase III Trial
    Zhang, Lifen
    Gao, Fan
    Zeng, Gang
    Yang, Haitao
    Zhu, Taotao
    Yang, Shuangmin
    Meng, Xing
    Mao, Qunying
    Liu, Xiaoqiang
    JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY, 2021, 10 (04) : 440 - 447
  • [48] Safety and Immunogenicity of Inactivated Varicella-Zoster Virus Vaccine in Adults With Autoimmune Disease: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Trial
    Eberhardson, Michael
    Hall, Stephen
    Papp, Kim A.
    Sterling, Tina M.
    Stek, Jon E.
    Pang, Lei
    Zhao, Yanli
    Parrino, Janie
    Popmihajlov, Zoran
    CLINICAL INFECTIOUS DISEASES, 2017, 65 (07) : 1174 - 1182
  • [49] Immunogenicity and Safety of a 3-Dose Regimen of a SARS-CoV-2 Inactivated Vaccine in Adults: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial
    Liu, Jiankai
    Huang, Baoying
    Li, Guifan
    Chang, Xianyun
    Liu, Yafei
    Chu, Kai
    Hu, Jialei
    Deng, Yao
    Zhu, Dandan
    Wu, Jingliang
    Zhang, Li
    Wang, Meng
    Huang, Weijin
    Pan, Hongxing
    Tan, Wenjie
    JOURNAL OF INFECTIOUS DISEASES, 2022, 225 (10): : 1701 - 1709
  • [50] Immunogenicity and safety of a 12-valent pneumococcal conjugate vaccine in infants aged 6-10 weeks: a randomized double-blind active-controlled trial
    Shin, Jonghoon
    Teeratakulpisarn, Jamaree
    Puthanakit, Thanyawee
    Theerawit, Tuangtip
    Ryu, Ji Hwa
    Shin, Jinhwan
    Lee, Seulgi
    Lee, Hayoung
    An, Kyungjun
    Kim, Hun
    CLINICAL AND EXPERIMENTAL PEDIATRICS, 2020, 63 (07) : 265 - 271